La traduzione di questa pagina è sperimentale e in fase di sviluppo. Siamo lieti di ricevere vostro !
Coherus BioSciences Gestione
Gestione criteri di controllo 3/4
Al momento non disponiamo di informazioni sufficienti sull'amministratore delegato.
Informazioni chiave
Denny Lanfear
Amministratore delegato
US$5.9m
Compenso totale
| Percentuale dello stipendio del CEO | 16.7% |
| Mandato del CEO | 14yrs |
| Proprietà del CEO | 1.0% |
| Durata media del management | 2.6yrs |
| Durata media del Consiglio di amministrazione | 3.2yrs |
Aggiornamenti recenti sulla gestione
Recent updates
Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 27% Dive
Sep 22
Evaluating Coherus BioSciences: Udenyca's Success And Loqtorzi's Prospects
Aug 13Why Investors Shouldn't Be Surprised By Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Low P/S
Aug 07Coherus BioSciences: CHS-114 Comes Into View At ASCO, Drug Launches Underway
May 31Shareholders May Be More Conservative With Coherus BioSciences, Inc.'s (NASDAQ:CHRS) CEO Compensation For Now
May 23Coherus Biosciences: Dumping One Drug But Showing Promise With Another
Mar 21Revenues Working Against Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Share Price Following 29% Dive
Feb 03Coherus BioSciences: FDA Approvals Spice Up The Pipeline
Jan 17Investors Aren't Buying Coherus BioSciences, Inc.'s (NASDAQ:CHRS) Revenues
Dec 20The Consensus EPS Estimates For Coherus BioSciences, Inc. (NASDAQ:CHRS) Just Fell Dramatically
May 13Coherus to launch its biosimilar to Roche's eye disorder drug Lucentis in U.S. on Oct. 3
Sep 19Coherus: 2022 Is In Many Ways A Make Or Break Year
Aug 24Coherus stock soars 14% on FDA nod for Roche Lucentis' interchangeable biosimilar Cimerli
Aug 03Coherus, Shanghai Junshi refiling for toripalimab gets FDA review in rare head/neck cancer
Jul 06Would Coherus BioSciences (NASDAQ:CHRS) Be Better Off With Less Debt?
Jun 15Coherus: Will Its Chinese Gambit Fail?
May 27Analisi delle retribuzioni degli amministratori delegati
| Data | Compenso totale | Stipendio | Guadagni aziendali |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$29m |
| Mar 31 2024 | n/a | n/a | -US$59m |
| Dec 31 2023 | US$6m | US$983k | -US$238m |
| Sep 30 2023 | n/a | n/a | -US$217m |
| Jun 30 2023 | n/a | n/a | -US$264m |
| Mar 31 2023 | n/a | n/a | -US$271m |
| Dec 31 2022 | US$7m | US$945k | -US$292m |
| Sep 30 2022 | n/a | n/a | -US$279m |
| Jun 30 2022 | n/a | n/a | -US$230m |
| Mar 31 2022 | n/a | n/a | -US$210m |
| Dec 31 2021 | US$9m | US$885k | -US$287m |
| Sep 30 2021 | n/a | n/a | -US$232m |
| Jun 30 2021 | n/a | n/a | -US$165m |
| Mar 31 2021 | n/a | n/a | -US$76m |
| Dec 31 2020 | US$7m | US$857k | US$132m |
| Sep 30 2020 | n/a | n/a | US$162m |
| Jun 30 2020 | n/a | n/a | US$181m |
| Mar 31 2020 | n/a | n/a | US$145m |
| Dec 31 2019 | US$5m | US$751k | US$90m |
| Sep 30 2019 | n/a | n/a | -US$12m |
| Jun 30 2019 | n/a | n/a | -US$118m |
| Mar 31 2019 | n/a | n/a | -US$185m |
| Dec 31 2018 | US$4m | US$702k | -US$209m |
| Sep 30 2018 | n/a | n/a | -US$196m |
| Jun 30 2018 | n/a | n/a | -US$196m |
| Mar 31 2018 | n/a | n/a | -US$208m |
| Dec 31 2017 | US$3m | US$656k | -US$238m |
Compensazione vs Mercato: La retribuzione totale di Denny ($USD 5.90M ) è superiore alla media delle aziende di dimensioni simili nel mercato US ($USD 681.57K ).
Compensazione vs guadagni: La retribuzione di Denny è stata coerente con le performance aziendali dell'ultimo anno.
AMMINISTRATORE DELEGATO
Denny Lanfear (69 yo)
14yrs
Mandato
US$5,897,924
Compensazione
Mr. Dennis M. Lanfear, also known as Denny, Co-founder, Chairman, Chief Executive Officer and President of Coherus Biosciences Inc. since September 2010. Mr. Lanfear serves as the President of Lanfear Capi...
Gruppo dirigente
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 14yrs | US$5.90m | 0.99% $ 1.2m | |
| Former Interim CFO | 2yrs | US$1.07m | 0.023% $ 27.7k | |
| Chief Commercial Officer | 3.7yrs | US$1.93m | 0.071% $ 85.3k | |
| Chief Technical Officer | 2.7yrs | Nessun dato | Nessun dato | |
| Vice President of Investor Relations | no data | Nessun dato | Nessun dato | |
| Executive Vice President of General Counsel | less than a year | Nessun dato | Nessun dato | |
| Vice President of Communications | no data | Nessun dato | Nessun dato | |
| Executive Vice President of Corporate Development | 1.7yrs | Nessun dato | Nessun dato | |
| Chief Human Resources Officer | no data | Nessun dato | Nessun dato | |
| Senior Vice President of Commercial Analytics & Trade | no data | Nessun dato | Nessun dato | |
| Chief Development Officer & Chairman of Scientific Advisory Board | 2.7yrs | Nessun dato | Nessun dato | |
| Chief Medical Officer | 2.5yrs | Nessun dato | Nessun dato |
2.6yrs
Durata media
56.5yo
Età media
Gestione esperta: Il team dirigenziale di CHRS è considerato esperto (durata media dell'incarico 2.5 anni).
Membri del Consiglio di amministrazione
| Nome | Posizione | Mandato | Compensazione | Proprietà |
|---|---|---|---|---|
| Chairman | 14yrs | US$5.90m | 0.99% $ 1.2m | |
| Chief Development Officer & Chairman of Scientific Advisory Board | 2.7yrs | Nessun dato | Nessun dato | |
| Lead Independent Director | 12.7yrs | US$228.69k | 0.087% $ 105.0k | |
| Independent Director | 3.7yrs | US$198.69k | 0.0076% $ 9.2k | |
| Independent Director | 10.3yrs | US$65.00k | 0% $ 0 | |
| Independent Director | 2.6yrs | US$186.19k | 0% $ 0 | |
| Member of Strategic Advisory Board | less than a year | Nessun dato | Nessun dato | |
| Independent Director | 2.3yrs | US$188.69k | 0% $ 0 | |
| Independent Director | 2.3yrs | US$183.69k | 0% $ 0 | |
| Independent Director | 4.2yrs | US$193.69k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.2yrs | Nessun dato | Nessun dato | |
| Member of Scientific Advisory Board | 3.2yrs | Nessun dato | Nessun dato |
3.2yrs
Durata media
60yo
Età media
Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di CHRS sono considerati esperti (durata media dell'incarico 3.1 anni).